Alzinova Ab · OMXSTO:ALZ
Alzinova Ab — Investor Presentation (October 2021)
19 slides from Alzinova Ab's investor presentation, Oct 19, 2021
Slide 1: Alzinova – Company Presentation
Alzinova – Company Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This information contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strate
Slide 3: Alzinova – developing first oligomer-specific vaccine against Alzheimer's disease
Alzinova – developing first oligomer-specific vaccine against Alzheimer’s disease Swedish biopharma company Based in Gothenburg. Founded: 2011 High unmet medical need for Alzheimer’s disease Innovative science and proprietary technology enables development of disease-modifying treatments for Alzheim
Slide 4: Alzheimer's disease is a progressively debilitating disease with the highest unmet medical need
Alzheimer’s disease is a progressively debilitating disease with the highest unmet medical need • >55 million patients have dementia (>130 million in 2050) • Alzheimer’s = 60-80% of all dementia • Impacts quality of life for patients and their families • Annual cost of dementia: US $1.3 trillion, es
Slide 5: Alzinova – product pipeline targeting Alzheimer's Disease
Alzinova – product pipeline targeting Alzheimer’s Disease Candidates Discovery Pre-clinical Clinical NDA/MAA Next Planned Milestone ALZ-1011) therapeutic H2 2023 Topline data vaccine clinical phase 1b ALZ-2012) monoclonal antibody 1) Phase 1b study in patients with Alzheimer’s 2) Humanization of mon
Slide 6: Alzinova's products are based on proprietary AβCC peptide technology
Alzinova’s products are based on proprietary AβCC peptide™ technology Alzinova's AβCC peptide™ technology enables development of high precision, disease- modifying therapies specifically targeting the neurotoxic oligomers 6 ©2021 Alzinova AB (publ), All rights reserved
Slide 7: Alzinova's products are based on proprietary AβCC peptide technology
Alzinova’s products are based on proprietary AβCC peptide™ technology Alzinova's AβCC peptide™ technology enables development of high precision, disease- modifying therapies specifically targeting the neurotoxic oligomers 7 ©2021 Alzinova AB (publ), All rights reserved
Slide 8: New generation anti-amyloidβ immunotherapy
New generation anti-amyloidβ immunotherapy Non-specific binding Non-specific binding Specific binding Aggregated Aβ Oligomer-specific targeting Aβ40 Aβ42 Toxic forms (oligomers) Insoluble Aβ forms (fibrils) Side effects (ARIA:s) Side effects (ARIA:s) Best in-class potential No clinical benefit Signs
Slide 9: Alzinova is developing two oligomer-specific products
Alzinova is developing two oligomer-specific products • Alzinova has two oligomer-specific products: − ALZ-101 vaccine (stable Aβ42CC oligomers) − ALZ-201 monoclonal antibody • Vaccines as a treatment modality offer advantages: − High patient compliance (few booster doses) − Cost effective − Prevent
Slide 10: ALZ-101 represents a potential breakthrough in Alzheimer's Disease
ALZ-101 represents a potential breakthrough in Alzheimer's Disease • Highly specific therapeutic vaccine, directed towards the neurotoxic oligomeric Aβ • Opportunity to become an effective and well tolerated treatment to halt and reverse Alzheimer’s • Best-in-class potential Immunotherapeutic drug c
Slide 11: ALZ-101 - strong data supporting clinical development
ALZ-101 - strong data supporting clinical development Transgenic mice vaccinated with ALZ-101 • Comprehensive package supporting clinical phase 1b study showed a 25% increase of synapse density compared to controls – ALZ-101 is well tolerated in non-clinical toxicity studies ✓ – Efficacy data in thr
Slide 12: ALZ-101 First in Human Study, phase 1b in patients with Alzheimer's disease - initiated
ALZ-101 First in Human Study, phase 1b in patients with Alzheimer’s disease - initiated Site Clinical Research Service Turku (CRST) Finland Subjects 26 patients - mild AD or MCI due to AD Study design Randomized, placebo controlled, double-blind Treatment Two different doses ALZ-101 and placebo Stud
Slide 13: Development of vaccine ALZ-101 and monoclonal antibody ALZ-201
Development of vaccine ALZ-101 and monoclonal antibody ALZ-201 ongoing and planned activities ALZ-101 vaccine – phase 2 ready • Phase 1b study, 1 year recruitment – ongoing • Long-term extension study of phase 1b – planning • Process optimization of manufacturing of peptide (ALZ-101) – ongoing • Pre
Slide 14: Alzinova's business model: develop, document, prepare, partner
Alzinova's business model: develop, document, prepare, partner • Develop novel disease-modifying immunotherapies based on proprietary AβCC technology • Document safety and tolerability in patients with Alzheimer’s disease • Prepare (in parallel) for phase 2 to optimize the value of the candidates •
Slide 15: Experienced management team and innovation-focused collaborations
Experienced management team and innovation-focused collaborations Kristina Torfgård, PhD Anders Sandberg, PhD Anders Bylock, MD, PhD Chief Executive Officer Chief Scientific Officer and Chief Medical Officer Co-Founder >25 years experience – >30 years experience – AstraZeneca, Albireo >20 years expe
Slide 16: Board of Directors with extensive pharma and biopharma experience
Board of Directors with extensive pharma and biopharma experience Björn Larsson Anders Blom Per-Göran Gillberg, PhD Chair of the Board >25 years experience – 35 years in experience – >25 years experience – Pharmacia & Upjohn, Q-Med AB, Kabi, Kabi Pharmacia, Pharmacia & Novo Nordisk, AstraZeneca, Nex
Slide 17: Summary: ALZ-101 represents a potential breakthrough for the treatment of Alzheimer's patients
Summary: ALZ-101 represents a potential breakthrough for the treatment of Alzheimer’s patients • High unmet medical need for disease-modifying treatments of Alzheimer’s disease • Short-term goal to initiate the first oligomer-specific clinical trial with a therapeutic vaccine in patients by Q3 2021
Slide 18: Capitalisation table, summary of shares and options
Capitalisation table, summary of shares and options Shareholders, as per 30 September 2021: Capitalization table (amounts in million SEK): Owner No. of shares Capital % Försäkrings AB Avanza Pension 1,790,581 11.35% Market cap, as per 30 Aug. 2021 126.2 Maida Vale Capital AB 1,734,332 10.99% Nordnet
Slide 19: Thank you!
alzinova® Thank you!